Enovis CORP ENOV

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived NYSE

Enovis Corporation (the "Company", "Enovis", "we" or "us") is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system ("EGX"), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.

Last close 21.08 2026-10-23
Market cap $1.22B 2026-07-03 share count
52-week range 16.70 - 34.28

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF61.0x
EV/EBITDA11.3x
Dividend yield—
Diluted EPS-20.75

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Foreign locations
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 1.3B (57.6%) 58% United States Foreign locations, FY2025: 952.7M (42.4%) 42% Foreign locations FY2024 United States, FY2024: 1.2B (59.1%) 59% Foreign locations, FY2024: 861.9M (40.9%) 41% FY2023 United States, FY2023: 1.2B (67.5%) 68% Foreign locations, FY2023: 554.8M (32.5%) 32%
Region FY2025FY2024FY2023
United States $1.30B $1.25B $1.15B
Foreign locations $952.7M $861.9M $554.8M

As the company reported it, from the “Segment Information Net Sales and PPE by Geography (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.25B$2.11B$1.71B$1.56B$1.43B$1.12B$3.33B$2.19B$1.94B$3.19B
Cost of revenue $902.8M$926.9M$716.4M$693.7M$648.5M$517.1M$1.93B$1.46B$1.27B$2.19B
Gross profit $1.35B$1.18B$990.8M$869.4M$777.7M$603.6M$1.40B$729.4M$671.6M$992.4M
R&D $120.3M$91.3M$75.3M$60.8M$49.1M$34.3M————
SG&A $1.07B$1.03B$830.3M$772.9M$665.8M$515.5M$1.13B$548.8M$500.6M$696.8M
Operating income -$1.12B-$775.7M-$65.7M-$71.2M-$62.8M-$66.2M$203.6M$151.5M$135.6M$236.8M
Interest expense $34.8M$57.1M$19.7M$24.1M$29.1M$52.8M$119.5M$49.1M$40.1M$30.3M
Pre-tax income -$1.16B-$822.9M-$67.1M-$2.1M-$121.8M-$119.0M$50.5M$92.4M$48.6M$206.5M
Income tax $22.3M$4.5M$13.3M$36.1M$19.5M$44.6M$31.6M$29.5M$2.5M$51.8M
Net income -$1.18B-$825.5M-$33.3M-$13.3M$71.7M$42.6M-$527.6M$140.2M$151.1M$128.1M
EPS, basic -20.75-14.93-0.61-0.251.400.93-3.891.171.231.04
EPS, diluted -20.75-14.93-0.61-0.251.400.93-3.891.161.221.04
Shares, diluted (wtd. avg.) 57.1M55.3M54.5M54.1M51.1M45.6M136.7M120.8M124.0M123.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $36.4M$48.2M$36.2M$24.3M$680.3M$97.1M$109.6M$77.2M$262.0M$208.8M
Short-term investments ————————$149.6M$0
Receivables $442.8M$407.0M$291.5M$267.4M$255.0M$517.0M$561.9M$386.6M$970.2M$838.8M
Inventory $584.4M$547.1M$468.8M$426.6M$356.2M$564.8M$571.6M$359.7M$429.6M$365.0M
Total current assets $1.21B$1.15B$896.5M$795.0M$2.30B$1.36B$1.40B$1.96B$2.07B$1.74B
Property, plant and equipment $507.1M$404.5M$270.8M$236.7M$235.1M$487.0M$491.2M$327.2M$552.8M$505.4M
Goodwill $718.3M$1.69B$2.06B$1.98B$92.4M$1.76B$3.20B$1.50B$1.43B$2.35B
Other intangibles $1.24B$1.32B$1.13B$1.11B$1.15B$1.66B$1.72B$628.3M$1.02B$916.3M
Total assets $3.83B$4.72B$4.51B$4.27B$8.52B$7.35B$7.39B$6.62B$6.71B$6.34B
Accounts payable $187.5M$179.1M$132.5M$135.6M$155.2M$330.3M$359.8M$291.2M$587.1M$515.5M
Short-term debt $35.0M$20.0M$0$219.3M$7.7M$27.1M$27.6M$5.0M$5.8M$5.4M
Total current liabilities $598.5M$529.0M$369.6M$565.2M$1.02B$811.7M$857.3M$1.20B$1.10B$1.06B
Long-term debt $1.26B$1.31B$466.2M$40.0M$2.08B$2.20B$2.28B$1.19B$1.06B$1.29B
Total liabilities $2.34B$2.15B$1.09B$823.4M$3.85B$3.76B$3.90B$3.14B$2.98B$3.25B
Retained earnings -$1.47B-$283.0M$542.5M$575.7M$589.0M$517.4M$479.6M$991.8M$846.5M$685.4M
Total equity $1.49B$2.56B$3.42B$3.45B$4.66B$3.59B$3.49B$3.48B$3.73B$3.09B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $217.3M$113.5M$135.0M-$55.9M$356.1M$301.9M$130.9M$226.4M$218.8M$247.0M
Depreciation and amortisation $1.34B$927.8M$217.1M$203.0M$187.0M$167.9M$215.6M$81.2M$72.7M$128.8M
Stock-based compensation $32.9M$29.7M$34.1M$39.0M$35.4M$28.9M$22.0M$25.1M$21.5M$19.0M
Capital expenditure $197.4M$180.7M$122.2M$105.5M$104.2M$114.8M$125.4M$69.6M$68.8M$63.3M
Investing cash flow -$179.4M-$955.5M-$242.5M-$176.4M-$320.5M-$175.1M-$1.63B-$167.9M$89.9M-$82.0M
Financing cash flow -$52.4M$846.8M$127.8M-$465.1M$584.9M-$131.7M$1.37B-$47.2M-$280.4M-$145.2M
Buybacks $3.5M$4.8M$0$0—$0$0$200.0M$0$20.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001420800-26-000012.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2B 0 2B 4B Revenue, FY2016: 3.2B Gross profit, FY2016: 992.4M Net income, FY2016: 128.1M Revenue, FY2017: 1.9B Gross profit, FY2017: 671.6M Net income, FY2017: 151.1M Revenue, FY2018: 2.2B Gross profit, FY2018: 729.4M Net income, FY2018: 140.2M Revenue, FY2019: 3.3B Gross profit, FY2019: 1.4B Net income, FY2019: -527.6M Revenue, FY2020: 1.1B Gross profit, FY2020: 603.6M Net income, FY2020: 42.6M Revenue, FY2021: 1.4B Gross profit, FY2021: 777.7M Net income, FY2021: 71.7M Revenue, FY2022: 1.6B Gross profit, FY2022: 869.4M Net income, FY2022: -13.3M Revenue, FY2023: 1.7B Gross profit, FY2023: 990.8M Net income, FY2023: -33.3M Revenue, FY2024: 2.1B Gross profit, FY2024: 1.2B Net income, FY2024: -825.5M Revenue, FY2025: 2.2B Gross profit, FY2025: 1.3B Net income, FY2025: -1.2B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $3.19B $1.94B $2.19B $3.33B $1.12B $1.43B $1.56B $1.71B $2.11B $2.25B
Gross profit $992.4M $671.6M $729.4M $1.40B $603.6M $777.7M $869.4M $990.8M $1.18B $1.35B
Net income $128.1M $151.1M $140.2M -$527.6M $42.6M $71.7M -$13.3M -$33.3M -$825.5M -$1.18B

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
STE STERIS plc $22.63B 29.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.80B 27.8x 7.2%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%